These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23196780)

  • 21. Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.
    Jani AB; Basu A; Abdalla I; Connell PP; Krauz L; Vijayakumar S
    Am J Clin Oncol; 2003 Aug; 26(4):382-5. PubMed ID: 12902891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
    Molenaar JP; Baten A; Blokx WA; Hoogendam A
    Eur Urol; 2009 Nov; 56(5):874-7; quiz 876. PubMed ID: 19171417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
    BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.
    Oh WK; Kaplan ID; Febbo P; Prisby J; Manola J; Kaufman DS; Kantoff PW
    Am J Clin Oncol; 2003 Jun; 26(3):312-6. PubMed ID: 12796607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
    Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
    Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer.
    Vuky J; Pham HT; Warren S; Douglass E; Badiozamani K; Madsen B; Hsi A; Song G
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e609-15. PubMed ID: 22208976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
    Slovin SF
    Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
    Iversen P; Roder MA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duration of androgen suppression in the treatment of prostate cancer.
    Bolla M; de Reijke TM; Van Tienhoven G; Van den Bergh AC; Oddens J; Poortmans PM; Gez E; Kil P; Akdas A; Soete G; Kariakine O; van der Steen-Banasik EM; Musat E; Piérart M; Mauer ME; Collette L;
    N Engl J Med; 2009 Jun; 360(24):2516-27. PubMed ID: 19516032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteosarcoma after radiotherapy for prostate cancer.
    Papalas JA; Wylie JD; Vollmer RT
    Ann Diagn Pathol; 2011 Jun; 15(3):194-7. PubMed ID: 20952292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).
    Anderson J; Al-Ali G; Wirth M; Gual JB; Gomez Veiga F; Colli E; van der Meulen E; Persson BE
    Urol Int; 2013; 90(3):321-8. PubMed ID: 23258223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
    Miller NL; Bissonette EA; Bahnson R; Wilson J; Theodorescu D
    Cancer; 2003 Mar; 97(5):1203-10. PubMed ID: 12599226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Locally advanced prostate cancer: definition, prognosis and treatment].
    Plantade A; Massard C; de Crevoisier R; Fizazi K
    Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).
    Parker C; Clarke N; Logue J; Payne H; Catton C; Kynaston H; Murphy C; Morgan R; Morash C; Parulekar W; Parmar M; Savage C; Stansfeld J; Sydes M;
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):167-71. PubMed ID: 17359901
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer.
    Dockery F; Bulpitt CJ; Agarwal S; Vernon C; Nihoyannopoulos P; Kemp M; Hooper J; Rajkumar C
    Clin Endocrinol (Oxf); 2008 Jan; 68(1):59-65. PubMed ID: 17692108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Results of 125-iodine seed implant with preplanning system in 250 patients with prostate cancer].
    Guinot JL; Ricós JV; Gimeno J; Tortajada MI; Carrascosa M; Santos M; Casanova J; Soler P; Crispín V; Arribas L
    Actas Urol Esp; 2011 Jun; 35(6):339-44. PubMed ID: 21481974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
    Lau YK; Chadha MK; Litwin A; Trump DL
    J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.